GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revance Therapeutics Inc (NAS:RVNC) » Definitions » 3-Year Revenue Growth Rate

Revance Therapeutics (Revance Therapeutics) 3-Year Revenue Growth Rate : 118.80% (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Revance Therapeutics 3-Year Revenue Growth Rate?

Revance Therapeutics's Revenue per Share for the three months ended in Mar. 2024 was $0.57.

During the past 12 months, Revance Therapeutics's average Revenue per Share Growth Rate was 36.40% per year. During the past 3 years, the average Revenue per Share Growth Rate was 118.80% per year. During the past 5 years, the average Revenue per Share Growth Rate was 160.70% per year. During the past 10 years, the average Revenue per Share Growth Rate was 72.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Revance Therapeutics was 467.00% per year. The lowest was -50.70% per year. And the median was 50.80% per year.


Competitive Comparison of Revance Therapeutics's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Revance Therapeutics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revance Therapeutics's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revance Therapeutics's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Revance Therapeutics's 3-Year Revenue Growth Rate falls into.



Revance Therapeutics 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Revance Therapeutics  (NAS:RVNC) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.


Revance Therapeutics 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Revance Therapeutics's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Revance Therapeutics (Revance Therapeutics) Business Description

Traded in Other Exchanges
Address
1222 Demonbreun Street, Suite 2000, Nashville, TN, USA, 37203
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
Executives
Dwight Moxie officer: SVP, GC & Secretary 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Mark J Foley director ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588
Tobin Schilke officer: Chief Financial Officer 7000 SHORELINE COURT, #371, SOUTH SAN FRANCISCO CA 94080
Carey Oconnor Kolaja director C/O REVANCE THERAPEUTICS, INC, 1222 DEMONBREUN STREET, SUITE 1001, NASHVILLE TN 37203
Dustin S Sjuts officer: President 7555 GATEWAY BLVD, NEWARK CA 94560
Vlad Coric director C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Aubrey Rankin director C/O REVANCE THERAPEUTICS, INC, 7555 GATEWAY BLVD, NEWARK CA 94560
Angus C. Russell director C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Olivia C Ware director 11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Chris Nolet director C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Jill Beraud director C/O LEVI STRAUSS & CO., 1155 BATTERY STREET, SAN FRANCISCO CA 94111
L Daniel Browne director, officer: CEO and President 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Cyril Allouche officer: Principal Financial Officer 7555 GATEWAY BLVD., NEWARK CA 94560
Lauren P Silvernail officer: CFO, Seretary & EVP Corp Dev. 15279 ALTON PARKWAY, SUITE #100, IRVINE CA 92618
Caryn Gordon Mcdowell officer: SVP, GC & Secretary 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080